liver fibrosis
Conditions
Interventions
F3: Severe fibrosis:None
F1: Mild fibrosis:None
F4: Cirrhosis:None
F2: Significant fibrosis:None
Healthy control group:None
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. According to the diagnostic criteria set by the National Health Commission, participants were selected from hospital physical examination centers, outpatient and inpatient CHB patients, liver cancer surgery patients, hemangioma surgery patients, and healthy individuals (all signed informed consent forms). 2. Before participating in the study, participants underwent tests including a ten-item immune panel, liver function, and HBV DNA testing to rule out co-infections with hepatitis A, C, D, and E viruses. Other liver diseases and immune system disorders such as fatty liver, alcoholic liver disease, autoimmune hepatitis, and drug-induced hepatitis were also excluded. Additionally, participants had not received any antiviral or immune-regulating treatments in the six months prior to enrollment. 3. Peripheral blood samples were collected from healthy individuals undergoing physical exams or from outpatient and inpatient CHB patients. 4. Healthy liver tissue was obtained from leftover samples from liver transplants or from normal liver tissue adjacent to surgically removed hemangiomas or metastatic liver tumors. Liver fibrosis samples were obtained from liver biopsy samples (mainly for immunohistochemical analysis) or from non-tumor tissue adjacent to liver cancer surgery specimens (HBsAg positive, with liver fibrosis).
Exclusion criteria
Exclusion criteria: 1. Patients under 18 or over 75 years old; 2. Co-infection with hepatitis A, C, D, or E virus; 3. Liver disease caused by other reasons, including but not limited to alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune liver disease, drug-induced liver injury, genetic metabolic liver disease, etc.; 4. HIV infection or other diseases that cause immune deficiency; 5. Received any antiviral treatment (such as nucleos(t)ide analogs, interferon), immunomodulators, or anti-fibrosis therapy within 6 months before enrollment; 6. Presence of hepatocellular carcinoma or other malignant tumors confirmed by imaging or pathology; 7. Pregnant or breastfeeding women; 8. Severe dysfunction of key organs such as heart, lungs, or kidneys; 9. Any other conditions deemed inappropriate for participating in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complications related to cirrhosis;Adverse Event/Serious Adverse Event; | — |
Countries
China
Contacts
Public ContactCheng Tian
Shanghai Public Health Clinical Center
Outcome results
None listed